The Sensus system is a non-invasive transcutaneous electrical nerve stimulator designed to relieve the symptoms of diabetic neuropathy. The device has a low, lightweight profile and is used to treat chronic pain in the lower leg and foot. The device landed FDA clearance in 2012.
The deal gives NeuroMetrix an established distributor to help with the commercialization of its device, as DJO has a direct U.S. sales force, according to a press release. DJO is a leading distributor of orthopedic devices, mainly in the rehabilitation and pain management range.
“DJO Global is a leader in the pain management market. The recovery sciences division includes EMPI, which is a long standing premier brand in the transcutaneous electrical nerve stimulator market. We believe that the national reach, talent, and subject matter expertise of the recovery sciences sales force will play a key role in accelerating Sensus adoption in the US market. We believe that this partnership will substantially expand patient access to the clinical benefits of Sensus pain therapy,” NeuroMetrix president & CEO Dr. Shai Gozani said in prepared remarks.
Waltham, Mass.-based NeuroMetrix also has a distribution deal with Omron Medical Devices, for its NC-stat DPNCheck diabetic peripheral neuropathy device in China. The deal will see Omron market the diabetic peripheral neuropathy device throughout China.